Offer your patients predictable bleed control and an established safety profile


*The pharmacokinetics of IXINITY have been evaluated in 32 previously treated patients (PTPs) ≥12 years of age with severe to moderately severe hemophilia B.1

Watch as real patients share their IXINITY IXperience™

Watch as real patients share their IXINITY IXperience

Success stories >

Find out if IXINITY is right for your patients

Patient profiles >

References: 1. IXINITY [coagulation factor IX (recombinant)]. Prescribing information. Chicago, IL: Medexus Pharma, Inc.; November 2022. 2. Data on file. Chicago, IL, Medexus Pharma, Inc.

The information in this section is intended for healthcare providers in the United States. I certify that I am a healthcare provider in the United States.